WS Investor
22 Feb 2025, 12:22
Charles River Laboratories International, Inc. announced that its Chair, President, and CEO, James C. Foster, purchased 6,075 shares of the company’s common stock at an average price of $165.01, totaling approximately $1 million. Additionally, Corporate Executive Vice President and Chief Operating Officer, Birgit Girshick, acquired 1,514 shares at an average price of $164.63, amounting to roughly $250,000. Both executives cited confidence in the company’s strategic direction and long-term growth prospects as reasons for their purchases.
To facilitate these transactions, Mr. Foster and Ms. Girshick terminated their respective Rule 10b5-1 Trading Plans, which had previously been established for selling company stock under predetermined conditions. Mr. Foster’s plan, initiated in February 2024, allowed for the sale of up to 129,721 shares, with 25,000 shares sold in August 2024. Ms. Girshick’s plan, established in November 2023, covered up to 22,362 shares, though no sales were made under it.
The company reaffirmed its confidence in its strategic initiatives and growth outlook while cautioning that forward-looking statements are subject to market risks and uncertainties.
To facilitate these transactions, Mr. Foster and Ms. Girshick terminated their respective Rule 10b5-1 Trading Plans, which had previously been established for selling company stock under predetermined conditions. Mr. Foster’s plan, initiated in February 2024, allowed for the sale of up to 129,721 shares, with 25,000 shares sold in August 2024. Ms. Girshick’s plan, established in November 2023, covered up to 22,362 shares, though no sales were made under it.
The company reaffirmed its confidence in its strategic initiatives and growth outlook while cautioning that forward-looking statements are subject to market risks and uncertainties.
